## TECH: Bio-Techne Corp - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.83 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-2.7% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($59.36)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Legal & General Group Plc Cuts Position in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251129T125150 | Neutral | Relevance: 99%
- Legal & General Group Plc reduced its stake in Bio-Techne Corp (NASDAQ:TECH) by 25.1% in the second quarter, selling 186,173 shares. Despite this, institutional ownership remains high at 98.95%, with other major investors increasing their positions. Bio-Techne reported mixed financial results, with EPS meeting expectations but revenue missing, and analysts maintain a "Moderate Buy" rating with a consensus price target of $70.92.

**2. Bio-Techne (TECH): Assessing Valuation After ACA Subsidy Extension Buzz Boosts Investor Sentiment**
- Source: Simply Wall Street | 20251129T102509 | Somewhat-Bullish | Relevance: 99%
- Investor sentiment for Bio-Techne (TECH) has improved due to news of a potential ACA subsidy extension, causing a recent share price rebound despite a negative one-year return. The company is considered 6.7% undervalued with a narrative fair value of $69.17, driven by a portfolio shift to higher-margin core businesses and accelerated innovation. However, its high P/E ratio of 129x compared to peers suggests investors are pricing in significant future growth, indicating potential risk if results disappoint.

**3. Rhumbline Advisers Has $15.16 Million Stock Holdings in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251201T103334 | Neutral | Relevance: 98%
- Rhumbline Advisers reduced its stake in Bio-Techne Corp by 1.9% in Q2, ending the quarter with 294,621 shares valued at $15.16 million. Bio-Techne reported Q2 EPS of $0.42 and revenue of $286.56 million, slightly below estimates. The company has a "Moderate Buy" rating from analysts with a consensus price target near $70.92.

**4. Swiss National Bank Has $15.52 Million Holdings in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251129T042211 | Neutral | Relevance: 98%
- The Swiss National Bank reduced its stake in Bio-Techne Corp ($TECH) by 32.7% in Q2, now holding 301,600 shares valued at approximately $15.52 million. This comes as Bio-Techne reported Q2 EPS of $0.42, meeting estimates, but revenue of $286.56 million missed expectations. The company also announced a quarterly dividend of $0.08 per share.

**5. Grandeur Peak Global Advisors LLC Has $7.13 Million Stock Position in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251201T094924 | Somewhat-Bullish | Relevance: 98%
- Grandeur Peak Global Advisors LLC significantly increased its stake in Bio-Techne Corp ($TECH) by 186.3% in Q2, bringing their total holdings to 138,514 shares valued at $7.13 million. Institutional investors now own 98.95% of the company, which has a market cap of $10.03 billion and a P/E ratio of 139.88. Analysts have a consensus "Moderate Buy" rating with an average price target of $70.92 for Bio-Techne, which recently reported Q2 earnings of $0.42 per share and revenue of $286.6 million.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Argus Research | $68 | $65 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Argus Research | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($0.43M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.5% (-2.7%)
- Blackrock Inc.: 7.6% (-2.3%)
- Morgan Stanley: 4.7% (+10.0%)
- State Street Corpora: 3.7% (-1.8%)
- Wellington Managemen: 3.3% (+349.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.83 indicates undervaluation relative to growth. Forward P/E 29.0x stretched relative to 11% growth. Balance sheet: strong liquidity (4.2x), low leverage (D/E 0.29). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.5B |
| Beta | 1.46 |
| 52W Range | $46.01 - $79.28 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.83 |
| Forward P/E | 29.0 |
| Current P/E | 32.2 |
| YoY Growth | 10.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 6.7% to 4.0% (-2.7% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 84th percentile. MRS_5 (-1.6%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 5.1% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.52), confirming momentum. RSI neutral at 58.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.04% (CS: 85) | Strong |
| RSI_14 | 58.4 | Neutral |
| MACD Histogram | 0.52 | Bullish |
| vs SMA20 | 1.051x | Above |
| vs SMA50 | 1.062x | Above |
| vs SMA200 | 1.148x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $63.76
- **Stop Loss:** $59.36 (6.9% risk)
- **Target:** $72.56 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 170
- **Position Value:** $10,839.20
- **Portfolio %:** 10.84%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-09 (Est: $0.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.42 | $0.42 | -0.4% |
| 2025Q2 | $0.50 | $0.53 | +5.8% |
| 2025Q1 | $0.51 | $0.56 | +10.4% |
| 2024Q4 | $0.39 | $0.42 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*